Ehrlichiosis pathophysiology

Jump to navigation Jump to search

Ehrlichiosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ehrlichiosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Prevention

Case Studies

Case #1

Ehrlichiosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ehrlichiosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ehrlichiosis pathophysiology

CDC on Ehrlichiosis pathophysiology

Ehrlichiosis pathophysiology in the news

Blogs on Ehrlichiosis pathophysiology

Directions to Hospitals Treating Ehrlichiosis

Risk calculators and risk factors for Ehrlichiosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ilan Dock, B.S.

Overview

The pathophysiological process of ehrlichiosis begins with the inoculation of the disease from a tick vector. Following inoculation ehrlichiae and anaplasmosis enter the circulatory system in an attempt to infect a target cell. The infectious agents will then enter the cell via a receptor-mediated endocytosis. This particular endocytosis process is facilitated by a glycophoshoinositol anchored receptor. Both the ehrlichiae and anaplasma complete their reproduction process within the host cell's endosome. Infectious agents of both disease are then able to reprogram a host cell's defense mechanisms in order to silently proliferate.

Pathophysiology

Pathogenesis of Human Monocytotropic Ehrlichiosis

  • E. chaffeensis enter into the mononuclear phagocytes.
  • Phagolysosome fusion is inhibited while host genes are suppressed and induced to enable intracellular replication.
  • Cytokines IL-12 and IL-18 are downregulated in THP-1 cells.
  • Genes that are responsible for upregulation of apoptosis such as SNAP 23, Rab5A and STX16 are downregulated in correlation to the downregulation of IL-12 and IL-18.
  • E. chaffeensis secretes an immunoreactive ankyrin protein (200kDa) into the host's nucleus in an attempt to manipulate the gene regulation of the host cell.
  • Other methods of E. chaffeensis include inhibiting the signal transduction pathway and circumventing host cell defense mechanisms.
  • Organ failure and other pathogenic manifestations resulting in complications or death is a result of immune mediated pathology.

Pathogenesis of Human Granulocytotropic Anaplasmosis

  • A.phagocytophilum successfully resides within the host cells (PMN cells) cytoplasmic vacuoles.
  • Apoptosis is suppressed due to the upregulation of bfl-1 and inhibiting anti-FAS. Both of which are responsible for inducing apoptosis within neutrophils.
  • Host cell gene transcription is controlled through a secreted protein, AnkA, that travels into the host cell's nucleus.
  • Research into the pathogensis of HGA has also shown upregulation of pro-inflammatory and IL-8 chemokines.
  • The pathogenesis of HGA causes immunosuppression and thus fatality may be attributed to opportunistic pathogens.

Transmission

  • Ehrlichia are transported between cells through the host cell filopodia during initial stages of infection, whereas, in the final stages of infection the pathogen ruptures the host cell membrane.[1]
  • Most of the symptoms of ehrlichiosis can likely be ascribed to the immune dysfunction that it causes.
  • Early in infection, production of TNF-alpha, a cellular product that promotes inflammation and immune response, is suppressed.
  • Experiments in mouse models further supports this hypothesis, as mice lacking TNF-alpha I/II receptors are resistant to liver injury caused by ehrlichia infection.
  • Late in infection, however, production of this substance can be upregulated by 30 fold, which is likely responsible for the "toxic shock-like" syndrome seen in some severe cases of ehrlichiosis.[2]

References

  1. Thomas S, Popov VL, Walker DH (2010). Kaushal, Deepak, ed. "Exit Mechanisms of the Intracellular Bacterium Ehrlichia". PLoS ONE. 5 (12): e15775. doi:10.1371/journal.pone.0015775. PMC 3004962. PMID 21187937.
  2. McBride, Jere W. (31 January 2011). "Molecular and cellular pathobiology of Ehrlichia infection: targets for new therapeutics and immunomodulation strategies". Expert Reviews in Molecular Medicine. 13. doi:10.1017/S1462399410001730. Unknown parameter |coauthors= ignored (help)